Drug Topics
OCTOBER 2, 2024
In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.
STAT
OCTOBER 2, 2024
U.S. health officials have run into obstacles in their efforts to determine whether a Missouri person infected with H5N1 bird flu passed the virus on to others, causing a delay that will likely fuel concerns about the possibility that there has been human-to-human transmission. The Centers for Disease Control and Prevention has blood samples from several health workers and a household contact of the Missouri case that it plans to test for antibodies that would indicate whether they too had been
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
OCTOBER 2, 2024
The designation was based on results from the DESTINY-Breast06 trial, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) compared with chemotherapy.
STAT
OCTOBER 2, 2024
Mapping the brain is a daunting task because it contains a huge number of cells and cell connections. It took almost 50 labs around the world to create a new neural map, or connectome, of an adult fruit fly — the largest map of its kind, and an effort that will allow researchers to better understand the brain’s inner workings. Access to the full connectome, as published Wednesday in a series of papers in Nature , could represent a new era for neuroscience, according to some re
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
OCTOBER 2, 2024
In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.
STAT
OCTOBER 2, 2024
For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s were misled into participating in ongoing Phase 3 clinical trials, so therefore, the Food and Drug Administration must take immediate steps to protect these vulnerable people from further harm.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 2, 2024
In a phase 1 trial, the nicotine replacement therapy (NRT) demonstrated a higher mean maximum plasma concentration was achieved faster than with an existing inhaled NRT.
Drug Topics
OCTOBER 2, 2024
Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.
Pharmacy Times
OCTOBER 2, 2024
Lowering prescription drug costs for patients, saving taxpayers money, helping small businesses level an anti-competitive playing field: all of this is at stake.
Drug Topics
OCTOBER 2, 2024
Investigators compared semaglutide and other glucagon-like peptide-1 receptor agonists with dipeptidyl peptidase-4 inhibitors.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
OCTOBER 2, 2024
Key federal lawmakers are pressuring the Drug Enforcement Administration to preserve health providers’ ability to prescribe a highly effective opioid addiction treatment via telehealth. In a letter delivered to the Biden administration on Wednesday, a bipartisan group led by Rep. Annie Kuster (D-N.H.) urged the DEA to continue allowing health providers to prescribe buprenorphine, a controlled substance used to treat opioid addiction, without requiring an in-person visit.
Drug Topics
OCTOBER 2, 2024
Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.
Fierce Pharma
OCTOBER 2, 2024
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.
Pharmacy Times
OCTOBER 2, 2024
In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
OCTOBER 2, 2024
Humana's stock took a tumble early on Wednesday after it revealed in a filing with the Securities and Exchange Commission that its Medicare Advantage star ratings had declined significantly. | Humana's stock took a tumble early on Wednesday after it revealed in a filing with the Securities and Exchange Commission that its Medicare Advantage star ratings had declined significantly.
STAT
OCTOBER 2, 2024
In 2023, Kentucky became the most recent state to pass a law prohibiting the denial of organ transplantation to patients solely because of their marijuana use. The legislation is scheduled to go into effect Jan. 1, 2025. Over the past 11 years, similar measures have been enacted in 21 other states. Though these laws overstep into medical decision-making, they are part of a rising trend.
Fierce Healthcare
OCTOBER 2, 2024
A proposed class action lawsuit brought by healthcare workers accusing UPMC of wielding its market power to suppress the labor market has picked up support from the U.S. Department of Justice. | The federal government filed a statement of interest in support of a proposed class action alleging the large nonprofit used its market power to suppress wages and worker mobility.
Pharmacy Times
OCTOBER 2, 2024
The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.
Fierce Healthcare
OCTOBER 2, 2024
TPG bought a majority stake in health information network Surescripts to fuel more investment in its technology solutions and possible M&A deals, the companies announced Tuesday. | PE firm TPG Capital bought a majority stake in Surescripts to fuel more investment in its technology solutions and possible M&A deals, the companies announced Tuesday.
STAT
OCTOBER 2, 2024
In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir, in 120 mostly low- and lower-middle-income countries. The move comes after a pair of late-stage clinical trials found the injectable medicine was highly effective in preventing HIV, paving the way for the company to seek regulatory approval for pre-exposure prophylaxis, or PrEP.
pharmaphorum
OCTOBER 2, 2024
A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.
STAT
OCTOBER 2, 2024
Blame the pickleball paddles. Over the past year, CVS has made a concerted push to court seniors to enroll in its Aetna Medicare programs by offering free sports equipment, fishing rods, and other enticements. It worked maybe a little too well for CVS, as the surge in new customers backfired when the medical costs for those sporty seniors spiraled well beyond the company’s expectations.
pharmaphorum
OCTOBER 2, 2024
In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%
STAT
OCTOBER 2, 2024
NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it. Farrell leaned forward enthusiastically to inspect data from a reporter’s Apple smartwatch showing that it hadn’t detected signs of sleep apnea.
Drug Topics
OCTOBER 2, 2024
The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.
Fierce Pharma
OCTOBER 2, 2024
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31
STAT
OCTOBER 2, 2024
Humana’s Medicare business has taken a financial beating all year, and it’s only going to get worse.
Fierce Pharma
OCTOBER 2, 2024
Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IR | New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.
STAT
OCTOBER 2, 2024
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide , also known as AMG 133. Results are coming before the end of the year. Novo Nordisk will report results of a Phase 3 study involving its obesity drug candidate CagriSema before the end of this year.
Fierce Healthcare
OCTOBER 2, 2024
The Centers for Medicare & Medicaid Services (CMS) rolled out guidance Oct. 2 as stakeholders prep for the second round of the drug price negotiation program. | CMS is looking to increase feedback from drug manufacturers and foster better communication with pharmacies as stakeholders prep for the next round of drug price negotiations.
STAT
OCTOBER 2, 2024
A pair of U.S. lawmakers is urging the Federal Trade Commission to investigate the parent companies of two large pharmacy benefit managers over concerns that new business units might unfairly steer patients toward higher-cost medicines. The effort comes after CVS Health and Cigna — which own CVS Caremark and Express Scripts, respectively — launched subsidiaries that are striking “co-manufacturing” deals with companies that make biologic medicines and lower-cost versio
Pharmacy Times
OCTOBER 2, 2024
Patients exhibited improved disease-free progression with minimal adverse effects.
pharmaphorum
OCTOBER 2, 2024
In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.
Pharmacy Times
OCTOBER 2, 2024
The findings support current recommendations for pregnant individuals or those who might become pregnant during the influenza season, specifically those with successive pregnancies.
Expert insights. Personalized for you.
201 
Let's personalize your content